TY - JOUR
T1 - A phase i trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer
T2 - A gynecologic oncology group study
AU - Moore, Kathleen N.
AU - Sill, Michael W.
AU - Miller, David S.
AU - McCourt, Carolyn
AU - De Geest, Koen
AU - Rose, Peter G.
AU - Cardenes, Higinia R.
AU - Mannel, Robert S.
AU - Farley, John H.
AU - Schilder, Russell J.
AU - Fracasso, Paula M.
PY - 2012/12
Y1 - 2012/12
N2 - Background: Epithelial growth factor receptor over-expression correlates with poor outcomes in cervical cancer. This study assessed the safety of chemoradiation with cetuximab in the treatment of women with newly diagnosed locally advanced cervical cancer. Methods: Patients received weekly cisplatin 30 and 40 mg/m2 [dose level (DL) 1 and 2] and cetuximab 400 mg/m 2 loading dose and then 250 mg/m2 for a total of six weeks with radiotherapy (RT). Patients with nodal metastases received extended field radiation therapy (EFRT). At the maximum tolerated dose, feasibility was evaluated in a 20 patient two-stage, sequential design. Results: In patients receiving pelvic RT, seven were treated at DL 1 with one dose-limiting toxicity (DLT) (febrile neutropenia with grade 3 diarrhea) and three at DL 2 with two DLTs (grade 3 rash and delay in RT > 8 weeks). The feasibility phase was opened at DL1. Of the 21 patients treated there was one DLT (grade 4 CVA). Median RT duration was 50 days (range, 42-70). In patients receiving EFRT, nine were treated at DL 1 with 1 DLT (grade 3 mucositis) and 24 in the feasibility phase with eight DLTs [delay in RT > 8 weeks due to toxicity (2) and one each with grade 3 or 4 small bowel obstruction, embolism, mucositis, mucositis with hypokalemia, pain with headache, and platelets with mucositis and headache]. Median EFRT duration was 56 days (range, 36-74). Conclusions: For patients receiving pelvic RT, cisplatin and cetuximab were feasible. For patients receiving EFRT, combination of cisplatin and cetuximab was not feasible.
AB - Background: Epithelial growth factor receptor over-expression correlates with poor outcomes in cervical cancer. This study assessed the safety of chemoradiation with cetuximab in the treatment of women with newly diagnosed locally advanced cervical cancer. Methods: Patients received weekly cisplatin 30 and 40 mg/m2 [dose level (DL) 1 and 2] and cetuximab 400 mg/m 2 loading dose and then 250 mg/m2 for a total of six weeks with radiotherapy (RT). Patients with nodal metastases received extended field radiation therapy (EFRT). At the maximum tolerated dose, feasibility was evaluated in a 20 patient two-stage, sequential design. Results: In patients receiving pelvic RT, seven were treated at DL 1 with one dose-limiting toxicity (DLT) (febrile neutropenia with grade 3 diarrhea) and three at DL 2 with two DLTs (grade 3 rash and delay in RT > 8 weeks). The feasibility phase was opened at DL1. Of the 21 patients treated there was one DLT (grade 4 CVA). Median RT duration was 50 days (range, 42-70). In patients receiving EFRT, nine were treated at DL 1 with 1 DLT (grade 3 mucositis) and 24 in the feasibility phase with eight DLTs [delay in RT > 8 weeks due to toxicity (2) and one each with grade 3 or 4 small bowel obstruction, embolism, mucositis, mucositis with hypokalemia, pain with headache, and platelets with mucositis and headache]. Median EFRT duration was 56 days (range, 36-74). Conclusions: For patients receiving pelvic RT, cisplatin and cetuximab were feasible. For patients receiving EFRT, combination of cisplatin and cetuximab was not feasible.
KW - Cervical cancer
KW - Cetuximab
KW - Pelvic radiation
UR - http://www.scopus.com/inward/record.url?scp=84868530868&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84868530868&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2012.08.030
DO - 10.1016/j.ygyno.2012.08.030
M3 - Article
C2 - 22960004
AN - SCOPUS:84868530868
VL - 127
SP - 456
EP - 461
JO - Gynecologic Oncology
JF - Gynecologic Oncology
SN - 0090-8258
IS - 3
ER -